Abstracts tagged "cardiovascular disease and biomarkers"

Abstract Number: 2038 • 2019 ACR/ARP Annual Meeting
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
Yangsheng Yu ¹, Michelene Hearth-Holmes ², Tammy Wang ¹, Perio D Lopez ³, Carmen Tineo ⁴, G Paulino ⁴, Michael Duryee ², Geoffrey Thiele ⁵, Ted Mikuls ⁵, Esthela Loyo ⁴ and Kaihong Su², ¹University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³Georgetown University, Washington DC, ⁴Hospital Regional Universitario José Ma Cabral Baez, San Diego, Dominican Republic, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by devastating end-organ manifestations. Cardiovascular disease (CVD) is a leading cause for premature death…
Abstract Number: 2355 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Thao Nguyen¹, Ingrid Hokstad ², Gia Deyab ³, Tom Eirik Mollnes ⁴, Stefan Agewall ⁴, Morten Fagerland ⁴, Gro Eilertsen ⁵, Mark Feinberg ⁶, Knut Mikkelsen ², Øystein Førre ⁴ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ³Innlandet Hospital Trust, Bærum, Akershus, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵The Artic University of Norway, Tromsø, Norway, ⁶Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Inflammation and immune dysregulation appear to significantly contribute to increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The complement system is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].